DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Efficacy and Safety of Cilostazol for the Indication of CSPS

Information source: Korea Otsuka Pharmaceutical Co.,Ltd.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cerebral Infarction

Phase: Phase 4

Status: Completed

Sponsored by: Korea Otsuka Pharmaceutical Co.,Ltd.

Official(s) and/or principal investigator(s):
Bo Youn Seo, Study Director, Affiliation: Korea Otsuka Pharmaceutical Co.,Ltd.

Summary

This is a multicenter, open-label, prospective study of cilostazol use for prevention of recurrence in patients with cerebral infarction.

Clinical Details

Official title: Post Marketing Surveillance of Efficacy and Safety of Cilostazol for the Indication of CSPS

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: 1)Efficacy:Recurrence of cerebral infarction 2)Safety:Adverse Event

Detailed description: This is a multicenter, open-label, prospective study of cilostazol use to prevention of recurrence in patients with cerebral infarction. Qualified patients will be treated with cilostazol by physician's assessment. This study will be continued for 4 years. More than 600 patients for 4 years.

Eligibility

Minimum age: 18 Years. Maximum age: 80 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patient with an experience of cerebral infarction and having a purpose for prevention

of recurrence of cerebral infarction.

- Age: more than 18 years of age

Exclusion Criteria:

- Unqualified patients judged by study investigator(s)

Locations and Contacts

Asan Medical Center, Seoul, Korea, Republic of
Additional Information

Starting date: December 2003
Last updated: December 15, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017